Cellzome gets €30mm with Series C private placement
Executive Summary
Cellzome (functional proteomics start-up) has raised €30mm ($32mm) with its Series C private placement. Lead investor Invesco Private Capital was joined by new investors BioFrontier Partners, SG Asset Management, and Yamanouchi Venture Capital. Existing investors included Advent International, Atlas Venture, Index Ventures, Heidelberg Innovation, Schroder Ventures Life Sciences, Sofinnova Partners, and Stelios Papadopoulos, vice chairman of SG Cowen, which also acted as placement agent for the financing.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice